Skip to main content

Table 2 Patients characteristics according to achievement of rapid virological response.

From: Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

Characteristic

Group A (n = 143)

Group B (n = 67)

P value

Male, no. (%)

116 (81)

54 (80)

NS

Age, years

42 (20-68)

45 (37-66)

NS

Body mass index, kg/m2

24 (22-32)

25 (21-30)

NS

V iral Load

   

   -<400.000 UI/ml

83(58)

22(33)

< 0.01

   ->400.000 UI/ml

60(42)

45(67)

< 0.01

Route of Trasmission

   

   -Intravenous drug use

94(66)

48(72)

NS

   -Transfusion

17(12)

9 (13)

NS

   - Unknown

32(22)

10(15)

NS

Alanine aminotransferase, IU/L

150(98-255)

145 (96-208)

NS

HCV genotype 2, n (%)

79 (55)

37 (55)

NS

HCV genotype 3, n (%)

64 (45)

30 (45)

NS

Cirrhosis (Ishak stage 5-6) n(%)

13 (9)

8 (12)

NS

Bridging fibrosis (Ishak stage 3-4) n(%)

26 (18)

15 (22)

NS

  1. All values are expressed as median (range) unless otherwise specified.